- AZN Stock Jumps On $2 Billion Bet In Weight-Loss Drugs Investor’s Business Daily
- AstraZeneca enters weight-loss market with oral GLP-1 drug Yahoo Finance
- AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug FierceBiotech
- AstraZeneca CFO: Obesity Market Has a Lot of Potential Bloomberg Television
- AstraZeneca makes big push into weight-loss market with obesity pill deal The Guardian
- View Full Coverage on Google News
